---

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

Date of Report: November 1, 2017
Commission File Number: 001-36891

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

---

---

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

Exhibit 99.1

Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting

NEW YORK--(BUSINESS WIRE)--November 1, 2017--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that abstracts regarding the Company's allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held from December 9 to 12, 2017 in Atlanta, GA.

Oral presentations:

• UCARTCS1 product candidate targeting Multiple Myeloma

502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper106073.html
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutic Strategies in Multiple Myeloma Session
Sunday, December 10, 2017 at 5:15 PM
Location: Bldg B, Lvl 3, B308-B309 (Georgia World Congress Center)

Rohit Mathur¹, Zheng Zhang¹, Jin He¹, Roman Galetto², Agnès Gouble², Isabelle Chion-Sotinel², Stéphanie Filipe², Annabelle Gariboldi², Tanooha Veeramachaneni¹, Elisabet E. Manasanch¹, Sheeba K. Thomas¹, Hans C. Lee¹, Krina K. Patel¹, Donna M. Weber¹, R. Eric Davis¹, Robert Z. Orlowski¹, Julianne Smith³, Jing Yang¹, and Sattva S. Neelapu¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
²Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France
³Cellectis Inc, 430 East 29th Street, 10016 New York, NY, USA

• UCART22 product candidate targeting B-Acute Lymphoblastic Leukemia

808. Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for the Treatment of B-cell Acute Lymphoblastic Leukemia

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105595.html
Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR-T Cell Immunotherapy
Monday, December 11, 2017: 5:15 PM
Location: Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Julia Wells PhD¹, Tianyu Cai, PhD¹, Cécile Schiffer-Manniou PhD², Stéphanie Filipe, PhD², Agnès Gouble, PhD², Roman Galetto, PhD², Nitin Jain MD¹, Elias Jabbour MD¹, Julianne SmithPhD³ and Marina Konopleva, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cellectis SA, Paris, France
³Cellectis Inc, New York, NY

Poster Presentation:

• UCART123 product candidate targeting Blastic Plasmacytoid Dendritic Cell Neoplasm

2625. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105789.html
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Sunday, December 10, 2017 from 6:00 PM to 8:00 PM
Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Tianyu Cai¹, Roman Galetto², Agnès Gouble², Julianne Smith³, Antonio Cavazos¹, Lina Han¹, Qi Zhang¹, Vinitha Kuruvilla¹, Sergej Konoplev⁴, Sattva S. Neelapu⁵, Andrew A. Lane⁶, Monica Guzman⁷, Hagop Kantarjian¹, Naveen Pemmaraju¹, Marina Konopleva¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cellectis SA, Paris, France
³Cellectis Inc, New York, NY
⁴Department of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX
⁵Department of Lymphoma and Myeloma, The University of MD Anderson Cancer Center, Houston, TX
⁶Dana-Farber Cancer Institute, Boston
⁷Department of Medicine, Weill Cornell Medical College, New York, NY

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

CONTACT:
For further information, please contact:
Media contacts:
Jennifer Moore, 917-580-1088
VP of Communications
media@cellectis.com
or
Caitlin Kasunich, 212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
or
IR contact:
Simon Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com

6